SkyAI, Inc. (Nasdaq: SKYA), formerly Sharps Technology, Inc., files with the SEC as a Nevada corporation with its principal executive office in Melville, New York, and a fiscal year that ends December 31. The annual report on Form 10-K and quarterly reports on Form 10-Q cover operating and financial results, with segment reporting that separates the digital asset treasury from the legacy medical device business, along with capital structure, material agreements, related-party consulting and advisory arrangements, and governance matters.
Current reports on Form 8-K record the change of name and ticker under Item 5.03, along with amended and restated bylaws that added advance notice requirements for stockholder proposals and director nominations and a Nevada exclusive forum provision. Other 8-Ks cover an updated code of business conduct and ethics under Item 5.05, annual meeting vote results under Item 5.07, officer appointments and employment agreements, a lock-up agreement with a strategic advisor, and, under Item 8.01, the special committee’s and the board’s conclusion on Forward Industries’ initial all-stock proposal.
The DEF 14A proxy statement covers the annual meeting, including director elections, ratification of the independent registered public accounting firm and an equity incentive plan, and describes the company’s repositioning from its medical device business to a digital asset treasury strategy. Registration statements on Form S-3 cover securities offerings. Insiders report their holdings and trades on Forms 3 and 4, and shareholders with stakes above five percent report them on Schedule 13D and Schedule 13G.
Sharps Technology (STSS) reported results of its special meeting of stockholders. Of 26,600,848 shares eligible to vote as of September 16, 2025, 17,779,090 shares were present or represented by proxy, establishing a 66.9% quorum.
Stockholders elected Annemarie Tierney as director with 17,770,289 votes for and 8,801 withheld. Proposal 2 was approved with 17,750,927 votes for, 27,713 against, and 450 abstentions. Proposal 3 was approved with 17,743,259 votes for, 35,546 against, and 285 abstentions. Proposal 4 was approved with 16,802,916 votes for, 51,835 against, and 924,339 abstentions.
Sharps Technology, Inc. approved a 2025 share repurchase program authorizing the company to buy back up to $100,000,000 of its outstanding common stock. The program allows repurchases in the open market and through negotiated transactions, with the amount and timing of purchases depending on available capital, financial and operational performance, market conditions, securities law limits, and other factors, and does not obligate the company to repurchase any shares.
To facilitate these buybacks, Sharps Technology entered into an Open Market Share Repurchase Agreement with Cantor Fitzgerald & Co., which will act as a non-exclusive agent to repurchase shares under Rule 10b-18 of the Exchange Act. The agreement remains in effect until either party terminates it by written notice, and the company will pay the broker a commission of $0.02 per share repurchased.
Sharps Technology, Inc. disclosed that its Board of Directors has authorized a stock repurchase program. This program allows the company to buy back its common shares in the open market and through negotiated transactions, which can reduce the number of shares available in the market over time. The announcement was made via a press release dated October 2, 2025, which is included as an exhibit to the report.
Reporting person Zhang Yuwen, Chief Investment Officer and director of Sharps Technology Inc. (STSS), reported a grant of stock options on 08/23/2025. The award consists of 500,000 stock options with an exercise price of $6.41 per share and a ten‑year term expiring on 08/22/2035. The options vest in four equal installments of 125,000 shares each, with 25% vesting every three months beginning on 08/23/2025. Following the grant, the reporting person beneficially owns 500,000 underlying common shares attributable to the options, held directly.
Sharps Technology Inc. (STSS) director and Chief Investment Officer Yuwen Zhang filed an initial Form 3 reporting indirect beneficial ownership of 14,040 shares of common stock that are held indirectly through a spouse. The event date listed is 08/23/2025 and the form is signed on 10/06/2025. No derivative securities (options, warrants, convertible instruments) are reported on this filing. The filing confirms the reporting person’s roles as a director and an officer (Chief Investment Officer), and discloses a pecuniary interest in the shares through family ownership.
Sharps Technology, Inc. entered into a confidential settlement agreement to resolve litigation with Barry Berler and several Plasto-related entities.
Under this settlement, Sharps will transfer certain assets to Plasto Technology Group LLC, including all of its right, title and interest in the issued and outstanding shares of its Hungarian subsidiary, Safegard Medical Kft, as well as specified patents, registered trademarks and associated goodwill.
All parties agree to unconditionally and irrevocably release one another and their representatives from all claims in the litigation, and the agreement specifies that no party admits fault, responsibility or liability. Sharps also provides unaudited pro forma condensed consolidated financial information as an exhibit to show the impact of these changes.
Sharps Technology, Inc. entered into a Waiver and Consent on September 26, 2025 with certain security holders who collectively beneficially own at least 50.1% of the outstanding Registrable Securities under its August 25, 2025 Registration Rights Agreement. This Waiver and Consent waives the original September 29, 2025 filing date and extends the deadline for Sharps Technology to file its initial resale registration statement with the SEC to the 60th calendar day following the Closing Date defined in that agreement. The company has filed the Waiver and Consent and the Registration Rights Agreement as exhibits for investors to review.
Sharps Technology, Inc. filed a Definitive Proxy Statement asking shareholders to vote on four proposals at a special meeting, principally the approval to issue up to 49,673,120 shares of common stock upon exercise of outstanding Cryptocurrency Warrants and a separate approval for issuance upon exercise of Strategic Advisor Warrants. The filing lists board nominees and executive officers, including Paul K. Danner as Executive Chairman and Principal Executive Officer and Andrew R. Crescenzo as CFO. The statement notes the threshold rule that an issuance equaling or exceeding 20% of outstanding common stock requires shareholder approval. Specific beneficial ownership lines are summarized with individual directors and officers holding less than 1% each.
Sharps Technology, Inc. submitted a Form S-3 shelf registration to offer multiple classes of securities, including common stock, preferred stock, warrants, purchase contracts, subscription rights, depositary shares and units combining those instruments. The filing includes a standard prospectus table of contents covering the prospectus summary, risk factors, use of proceeds, description of securities, plan of distribution and exhibits.
The document highlights industry risk linked to the Solana cryptocurrency ecosystem, noting uncertainty from factors such as worldwide adoption of SOL, regulatory or access restrictions, maintenance of open-source protocols, shifts in consumer preferences and general economic and regulatory conditions affecting cryptocurrency service providers. The filing discloses estimated offering-related fees and expenses with a total of $153,100 and attaches standard exhibits including forms of underwriting and security agreements and legal and auditor consents.